Impact of DPYD variants in Fluoropyrimidine based-therapy: the state of the art WCRJ 2014; 1 (3): e279
Pharmacogenomics markers for prediction response and toxicity in cancer therapy WCRJ 2014; 1 (3): e276
If the aim is ovarian cancer prevention and estrogen mediated benefits, not only endometriosis suppression, are contraceptives with ethinilestradiol better than progestogens alone? WCRJ 2014; 1 (3): e273
Advanced Lung cancer and age: is it still important to take it into account in the algorithm of decision-therapy? WCRJ 2014; 1 (3): e269
Improvement the life of quality, in preserving fertility by hormone suppressor Goserelin in female cancer patients could be cost-effectiveness WCRJ 2014; 1 (3): e267
Minimization of the neuropathic effects of oxalipaltin administration agree to cost-effectiveness WCRJ 2014; 1 (3): e264
Results of large abdominal wall resection repaired with biomaterial during HIPEC following cytoreductive surgery for peritoneal metastases WCRJ 2014; 1 (2): e250
Safety and efficacy of oxaliplatin-based chemotherapy in the first line treatment of elderly patients affected by metastatic colorectal cancer WCRJ 2014; 1 (2): e235